FDA Rejects Amryt Pharma's Oleogel-S10 Application For Skin Blistering Disorder


Amryt Pharma Plc AMYT has received a Complete Response Letter (CRL) from the FDA regarding Oleogel-S10 application for cutaneous manifestations of Dystrophic and Junctional Epidermolysis Bullosa (EB).

  • EB is a rare, genetic skin disease characterized by extremely fragile skin that blisters and tears from minor friction or trauma.
  • The FDA has asked Amryt to submit additional confirmatory evidence of effectiveness for Oleogel-S10 in EB. 
  • Amryt intends to discuss the nature of the data required to address the concerns with the FDA.
  • Also See: Amryt Shares Fall After Oleogel-S10 EMA Regulatory Update.
  • Joe Wiley, CEO of Amryt Pharma, commented: "We are extremely disappointed by this decision, and we remain committed to our goal of bringing Oleogel-S10 to patients...The EASE study was the largest randomized clinical trial ever conducted in this disease and the first Phase 3 study to meet its primary endpoint."
  • Price Action: AMYT shares are down 17.6% at $6.70 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapFDAMoversTrading IdeasGeneralBriefsComplete Response Letterwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!